Stock Events

Stock Events

DBV Technologies 

€3.58
54
+€0.14+4.08% Today

Statistics

Day High
3.44
Day Low
3.44
52W High
4.15
52W Low
0.71
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MayExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.56
-0.38
-0.21
-0.03
Expected EPS
-0.0293564869
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-218.52MNet Income

Analyst Ratings

$35.28Average Price Target
The highest estimate is 38.70.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DBV.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, involved in developing treatments for allergies and inflammatory diseases, competing in the broader allergy treatment market.
Sanofi
SNY
Mkt Cap124.45B
Sanofi, a large pharmaceutical company with a focus on immunology and allergy treatments, including collaborations on therapies that could compete with DBV's offerings.
Novavax
NVAX
Mkt Cap1.36B
Novavax, works on vaccines that could potentially address allergies, indirectly competing by targeting the underlying causes of allergic reactions.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for mRNA technology, which could be applied to develop vaccines or treatments for allergies, potentially competing with DBV's approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical, focuses on rare diseases but has interests in developing treatments that could overlap with allergy and immunotherapy markets.
Adma Biologics
ADMA
Mkt Cap3.69B
ADMA Biologics, specializes in immune globulin products which could be used in treating allergies, offering an alternative to DBV's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals, while primarily focused on cystic fibrosis, its research into other areas of medicine could lead to competitive treatments in the allergy space.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, a large pharmaceutical company with a diverse portfolio, including respiratory and allergy treatments, potentially competing across several areas of DBV's interest.

About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Show more...
CEO
Mr. Daniel Tassé
Employees
117
Country
FR
ISIN
FR0010417345
WKN
000A1JWB7

Listings

F
DE
DBV1.F
XETRA
DE
DBV.XETRA
F
DE
DBV.F
OTC Link
US
DBVTF

0 Comments

Share your thoughts

FAQ

What is DBV Technologies stock price today?▼
The current price of DBV.F is €3.58 EUR — it has increased by +4.08% in the past 24 hours. Watch DBV Technologies stock price performance more closely on the chart.
What is DBV Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange DBV Technologies stocks are traded under the ticker DBV.F.
Is DBV Technologies stock price growing?▼
DBV.F stock has risen by +8.17% compared to the previous week, the month change is a -6.29% fall, over the last year DBV Technologies has showed a +175% increase.
When is the next DBV Technologies earnings date?▼
DBV Technologies is going to release the next earnings report on May 04, 2026.
What were DBV Technologies earnings last quarter?▼
DBV.F earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.06 EUR resulting in a +24.66% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is DBV Technologies revenue for the last year?▼
DBV Technologies revenue for the last year amounts to 0 EUR.
What is DBV Technologies net income for the last year?▼
DBV.F net income for the last year is -218.52M EUR.
How many employees does DBV Technologies have?▼
As of April 01, 2026, the company has 117 employees.
In which sector is DBV Technologies located?▼
DBV Technologies operates in the Health Care sector.
When did DBV Technologies complete a stock split?▼
The last stock split for DBV Technologies was on June 07, 2024 with a ratio of 1:2.
Where is DBV Technologies headquartered?▼
DBV Technologies is headquartered in Châtillon, FR.